Plant Name: Robinia pseudoacacia
Taxonomic Information:
Plant ID: NPO3634
Plant Latin Name: Robinia pseudoacacia
Taxonomy Genus: Robinia
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
35938
Plant-of-the-World-Online:
30034699-2
Used in Medicines:
Country/Region:
Turkey; Italy; China; IndiaTraditional Medicine System:
TCMMedicinal Functions:
Antispasmodic; Antiviral; Aromatic; Cancer; Cholagogue; Diuretic; Emetic; Emollient; Febrifuge; Laxative; Narcotic; Purgative; Tonic
Geographical Distribution:
Turkey; Italy; Turkmenistan; France; Georgia; Argentina; Uzbekistan; Belarus; Algeria; China; Chile; Belgium; Germany; Iraq; Kazakhstan; Spain; Ukraine; Netherlands; Libya; United States; Morocco; Uruguay; Switzerland; New Zealand; Russia; Bulgaria; Pakistan; Romania; Albania; Mexico; South Africa; India; United Kingdom; Austria; Greece; Hungary; Taiwan; Tajikistan
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TDP1; AKR1B1; | |
| CDK8; MAPK1; | |
| CA2; CA1; CA7; CA12; CA9; CA14; | |
| HIF1A; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.190E-12 | 1.295E-08 | CA1, CA12, CA14, CA2, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 8.592E-11 | 3.118E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.025E-10 | 3.188E-07 | CA1, CA12, CA2, CA7, CA9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.306E-10 | 9.000E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.434E-09 | 5.889E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.597E-09 | 7.121E-06 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.131E-08 | 1.758E-05 | CYP1A2, CYP2C19, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 6.858E-08 | 7.111E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.240E-07 | 1.101E-04 | CYP1A2, CYP2C19, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.091E-07 | 1.687E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 9.919E-07 | 7.522E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.186E-06 | 1.286E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 2.186E-06 | 1.286E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.370E-06 | 2.213E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.370E-06 | 2.213E-03 | CYP1A2, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 6.259E-06 | 3.029E-03 | CA2, CYP1A1, CYP1A2, HIF1A, MAPK1 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 7.279E-06 | 3.446E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.091E-05 | 4.850E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 1.091E-05 | 4.850E-03 | CA1, CA2 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 1.527E-05 | 6.650E-03 | CYP1A2, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0033554; cellular response to stress | 1.931E-05 | 7.787E-03 | AKR1B1, CA2, CA9, CYP1B1, HIF1A, LMNA, MAPK1, TDP1 |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 2.035E-05 | 8.057E-03 | CYP1A1, CYP1A2 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 2.414E-05 | 9.222E-03 | CA2, CA9, CYP1A1, CYP1A2, CYP1B1, MAPK1 |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 2.620E-05 | 9.507E-03 | AKR1B1, HIF1A, MAPK1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 8.555E-16 | 1.863E-11 | CA1, CA12, CA14, CA2, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.715E-15 | 1.904E-13 | CA12, CA1, CA2, CA7, CA9, CA14 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 6.095E-09 | 3.383E-07 | CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.473E-07 | 5.450E-06 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.750E-07 | 1.041E-05 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 4.943E-06 | 9.144E-05 | CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.839E-06 | 4.082E-05 | CYP1A2, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 2.157E-05 | 3.420E-04 | CYP1A2, CYP1A1, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 2.581E-05 | 3.582E-04 | CYP1A2, CYP3A4, CYP2C19 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; MAPK1; CA1; CA9; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; MAPK1; CA9; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Edema | NA | CA2; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
